Concepedia
Statistics
Publications
10
Citations
549
H-Index
Active since
1998
Affiliations
University of Wisconsin–Madison(Current)
Spanish Oncology Genitourinary Group
University of Wisconsin System
University of Wisconsin Carbone Cancer Center
Kim Binger is an author at University of Wisconsin–Madison specializing in oncology, medicine, and pharmacology.
Top concepts
MedicineOncologyPharmacologyCancer TherapyCancer ResearchRadiation OncologyPathologyPharmacotherapyPharmacokineticsMolecular Oncology
Publications per year
1998–2006
A Phase I Trial of Perifosine (NSC 639966) on a Loading Dose/Maintenance Dose Schedule in Patients with Advanced Cancer
Lynn Van Ummersen, Kim Binger, Jennifer Volkman et al. · Clinical Cancer Research · 2004 · 157 citations
Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day.
Gregory H. Ripple, Michael N. Gould, Rhoda Arzoomanian et al. · PubMed · 2000 · 106 citations
Chemoprevention Strategy, Pharmacokinetic Study, Pharmacotherapy +20
A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer
Grace K. Dy, James P. Thomas, George Wilding et al. · Clinical Cancer Research · 2005 · 66 citations · Full text
Phase I and Pharmacokinetic Study of Prinomastat, a Matrix Metalloprotease Inhibitor
Kenneth R. Hande, Mary Collier, Linda J. Paradiso et al. · Clinical Cancer Research · 2004 · 51 citations · Full text
Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: A phase I subset analysis
Joan H. Schiller, K. T. Flaherty, Maryann Redlinger et al. · Journal of Clinical Oncology · 2006 · 50 citations
Tumor Biology, Oral Sorafenib, Medicine +14
1–5 of 10